RSV250

Establishing Interprofessional Clinical Pathways to Prevent Pediatric RSV

Train the Trainer

According to the CDC, up to 3% of children in their first year of life are hospitalized due to respiratory syncytial virus (RSV) each year, making it the leading cause of hospitalization among infants in the US. In addition, although prematurity and certain health problems increase the risk for severe RSV, most children hospitalized for RSV in the US have no underlying health conditions or history of preterm birth.

To prevent severe RSV disease in infants, available guidance recommends immunization with nirsevimab for all infants aged <8 months born during or entering their first RSV season (generally October through March), ideally during the birth hospitalization. However, with the availability of this novel preventive approach as well as the availability of a maternal RSV vaccine, many clinicians may have questions surrounding optimal RSV prevention strategies.

To support translation and implementation of the latest recommendations into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.

Faculty: Joseph Domachowske, MD, FAAP, FPIDS; Kaitlyn Rivard, PharmD

Release Date: April 15, 2025

Expiration Date: April 15, 2026